MediciNova, Inc.

Equities

MNOV

US58468P2065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
1.42 ^USD	-0.70%		-7.19%	-5.33%

05-14	MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	CI
05-09	MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166

May 07, 2024 at 11:00 am

MediciNova, Inc. announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166 (ibudilast). This new patent is expected to commence no earlier than September 2040. The allowed claims cover a formulation in the form of a tablet or capsule and cover a range of doses of MN-166 (ibUDilast).

Latest news about MediciNova, Inc.

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	05-14	CI
MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166	05-07	CI
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	03-26	CI
Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology	03-12	CI
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-15	CI
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China	01-17	CI
Top Premarket Gainers	01-12	MT
MediciNova, Inc. Announces Abstract Regarding MN-166 in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	12-21	CI
MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 for the Treatment of Progressive MS in Europe	12-06	CI
Sector Update: Health Care Stocks Lean Down Premarket Monday	11-20	MT
MediciNova Says Glioblastoma Phase 2 Trial of Therapy Combo Showed Progression-Free Survival of 44% at Six Months	11-20	MT
MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
MediciNova Secures Patent Notice of Allowance in Canada for Amyotrophic Lateral Sclerosis Combination Treatment	11/10/23	MT
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Canada	10/10/23	CI
MediciNova Says it Received $1 Million Clinical Development Milestone Payment Under Deal With Sanofi Subsidiary	05/10/23	MT
Sector Update: Health Care Stocks Gain Premarket Thursday	28/09/23	MT
MediciNova Says Ibudilast Improved Pulmonary Function in Lung Injury Study	28/09/23	MT
MediciNova, Inc. Announces Results of Studies Under BARDA Contract to Develop MN 166 as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury	27/09/23	CI
MediciNova Announces Abstract Regarding MN-166 in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology	18/08/23	CI
MediciNova Says European Patent Office Issued Notice of Intention to Grant on Macular Injury Therapy Application	17/08/23	MT
MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 for the Treatment of Macular Injury in Europe	16/08/23	CI
Sector Update: Health Care Stocks Steady Premarket Wednesday	16/08/23	MT
Fed Minutes Anticipation Lifts Exchange-Traded Funds, Equity Futures Slightly Premarket Wednesday	16/08/23	MT
MediciNova Says European Patent Office Granted New Patent Covering Scleroderma, Systemic Sclerosis Treatment	16/08/23	MT

Chart MediciNova, Inc.

Duration

Period

More charts

Company Profile

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Sector

Biotechnology & Medical Research

Calendar

02/06/2024 - American Society of Clinical Oncology Annual Meeting - Abstract Number: 2106

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.42 USD

Average target price

17 USD

Spread / Average Target

+1,097.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDICINOVA, INC.	-5.33%	69.65M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs